Molecular determinants of the cardiometabolic phenotype

Endocrine, Metabolic and Immune Disorders - Drug Targets

Volumn 10, Issue 2, 2010, Pages 109-123

  de las Fuentes, Lisa ^a   de Simone, Giovanni ^b   Arnett, Donna K ^c   Dávila Román, Víctor G ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FEDERICO II UNIVERSITY HOSPITAL   (Italy)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Cardiometabolic syndrome; Dyslipidemia; Hypertension; Inflammation; Insulin resistance; Metabolic syndrome; Obesity; Substrate metabolism

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPOCYTOKINE; ANTIINFLAMMATORY AGENT; C REACTIVE PROTEIN; ETANERCEPT; FATTY ACID; FIBRIC ACID DERIVATIVE; FIBRINOGEN; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 4; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; OSTEOPONTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECOMBINANT LEPTIN; RIMONABANT; ROSIGLITAZONE; SULFONYLUREA; TELMISARTAN; TRIACYLGLYCEROL; UNINDEXED DRUG;

ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CARDIOMETABOLIC SYNDROME; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIABETES MELLITUS; DIASTOLIC DYSFUNCTION; ENERGY; FATTY ACID TRANSPORT; FLUID RETENTION; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HERITABILITY; HOMEOSTASIS; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIPID OXIDATION; LIPODYSTROPHY; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; PHENOTYPE; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HEART FAILURE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 77954080527     PISSN: 18715303     EISSN: None     Source Type: Journal    
DOI: 10.2174/187153010791213119     Document Type: Article

References (250)

1. Ford, E.S.; Giles, W.H. and Dietz, W.H. (2002) Prevalence of the metabolic syndrome among US adults: findings from the Third Na- tional Health and Nutrition Examination Survey. JAMA, 287, 356-359.
2. Lakka, H.M.; Laaksonen, D.E.; Lakka, T.A.; Niskanen, L.K.; Kumpusalo, E.; Tuomilehto, J. and Salonen, J.T. (2002) The meta- bolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA, 288, 2709-2716.
3. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). (2002) Circulation, 106, 3143-3421.
4. Alberti, K.G.; Zimmet, P.; Shaw, J. and Group, I.D.F.E.T.F.C. (2005) The metabolic syndrome--a new worldwide definition. Lancet, 366, 1059-1062.
5. Alexander, C.M.; Landsman, P.B.; Teutsch, S.M. and Haffner, S.M. (2003) NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III partici- pants age 50 years and older. Diabetes, 52, 1210-1214.
6. de las Fuentes, L.; Brown, A.L.; Mathews, S.J.; Waggoner, A.D.; Soto, P.F.; Gropler, R.J. and Davila-Roman, V.G. (2007) Metabolic syndrome is associated with abnormal left ventricular diastolic function independent of left ventricular mass. Eur. Heart J., 28, 553-559.
7. Burchfiel, C.M.; Skelton, T.N.; Andrew, M.E.; Garrison, R.J.; Arnett, D.K.; Jones, D.W. and Taylor, H.A.Jr. (2005) Metabolic syndrome and echocardiographic left ventricular mass in blacks: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation, 112, 819-827.
8. Scuteri, A.; Najjar, S.S.; Muller, D.C.; Andres, R.; Hougaku, H.; Metter, E.J. and Lakatta, E.G. (2004) Metabolic syndrome ampli- fies the age-associated increases in vascular thickness and stiffness. J. Am. Coll. Cardiol., 43, 1388-1395.
9. Yarnell, J.W.; Patterson, C.C.; Bainton, D. and Sweetnam, P.M. (1998) Is metabolic syndrome a discrete entity in the general popu- lation? Evidence from the Caerphilly and Speedwell population studies. Heart, 79, 248-252.
10. de Simone, G.; Olsen, M.H.; Wachtell, K.; Hille, D.A.; Dahlof, B.; Ibsen, H.; Kjeldsen, S.E.; Lyle, P.A. and Devereux, R.B. (2007) Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study. J. Hum. Hypertens., 21, 625-632.
11. de Simone, G.; Devereux, R.B.; Chinali, M.; Best, L.G.; Lee, E.T.; Galloway, J.M.; Resnick, H.E. and Investigators, S.H.S. (2007) Prognostic impact of metabolic syndrome by different definitions in a population with high prevalence of obesity and diabetes: the Strong Heart Study. Diabetes Care, 30, 1851-1856.
12. Malik, S.; Wong, N.D.; Franklin, S.S.; Kamath, T.V.; L'Italien, G.J.; Pio, J.R. and Williams, G.R. (2004) Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation, 110, 1245-1250.
13. Schillaci, G.; Pirro, M.; Pucci, G.; Mannarino, M.R.; Gemelli, F.; Siepi, D.; Vaudo, G. and Mannarino, E. (2006) Different impact of the metabolic syndrome on left ventricular structure and function in hypertensive men and women. Hypertension, 47, 881-886.
14. Leoncini, G.; Ratto, E.; Viazzi, F.; Vaccaro, V.; Parodi, D.; Parodi, A.; Falqui, V.; Tomolillo, C.; Deferrari, G. and Pontremoli, R. (2005) Metabolic syndrome is associated with early signs of organ damage in nondiabetic, hypertensive patients. J. Intern. Med., 257, 454-460.
15. McNeill, A.M.; Rosamond, W.D.; Girman, C.J.; Heiss, G.; Golden, S.H.; Duncan, B.B.; East, H.E. and Ballantyne, C. (2004) Preva- lence of coronary heart disease and carotid arterial thickening in patients with the metabolic syndrome (The ARIC Study). Am. J. Cardiol., 94, 1249-1254.
16. Rutter, M.K.; Meigs, J.B.; Sullivan, L.M.; D'Agostino, R.B.Sr. and Wilson, P.W. (2005) Insulin resistance, the metabolic syndrome, and incident cardiovascular events in the Framingham Offspring Study. Diabetes, 54, 3252-3257.
17. Sattar, N.; Gaw, A.; Scherbakova, O.; Ford, I.; O'Reilly, D.S.; Haffner, S.M.; Isles, C.; Macfarlane, P.W.; Packard, C.J.; Cobbe, S.M. and Shepherd, J. (2003) Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation, 108, 414-419.
18. Ingelsson, E.; Arnlov, J.; Lind, L. and Sundstrom, J. (2006) Meta- bolic syndrome and risk for heart failure in middle-aged men. Heart, 92, 1409-1413.
19. Zeller, M.; Steg, P.G.; Ravisy, J.; Laurent, Y.; Janin-Manificat, L.; L'Huillier, I.; Beer, J.C.; Oudot, A.; Rioufol, G.; Makki, H.; Farnier, M.; Rochette, L.; Verges, B. and Cottin, Y. (2005) Preva- lence and impact of metabolic syndrome on hospital outcomes in acute myocardial infarction. Arch. Intern. Med., 165, 1192-1198.
20. Ninomiya, J.K.; L'Italien, G.; Criqui, M.H.; Whyte, J.L.; Gamst, A. and Chen, R.S. (2004) Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation, 109, 42-46.
21. Gami, A.S.; Witt, B.J.; Howard, D.E.; Erwin, P.J.; Gami, L.A.; Somers, V.K. and Montori, V.M. (2007) Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J. Am. Coll. Cardiol., 49, 403-414.
22. Hunt, K.J.; Resendez, R.G.; Williams, K.; Haffner, S.M. and Stern, M.P. (2004) National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation, 110, 1251-1257.
23. Huang, P.; Kraja, A.T.; Tang, W.; Hunt, S.C.; North, K.E.; Lewis, C.E.; Devereux, R.B.; de Simone, G.; Arnett, D.K.; Rice, T. and Rao, D.C. (2008) Factor relationships of metabolic syndrome and echocardiographic phenotypes in the HyperGEN study. J. Hypertens., 26, 1360-1366.
24. de Simone, G.; Palmieri, V.; Bella, J.N.; Celentano, A.; Hong, Y.; Oberman, A.; Kitzman, D.W.; Hopkins, P.N.; Arnett, D.K. and Devereux, R.B. (2002) Association of left ventricular hypertrophy with metabolic risk factors: the HyperGEN study. J. Hypertens., 20, 323-331.
25. Despres, J.P.; Lemieux, I.; Bergeron, J.; Pibarot, P.; Mathieu, P.; Larose, E.; Rodes-Cabau, J.; Bertrand, O.F. and Poirier, P. (2008) Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler. Thromb. Vasc. Biol., 28, 1039-1049.
26. Chinali, M.; Devereux, R.B.; Howard, B.V.; Roman, M.J.; Bella, J.N.; Liu, J.E.; Resnick, H.E.; Lee, E.T.; Best, L.G. and de Simone, G. (2004) Comparison of cardiac structure and function in Ameri- can Indians with and without the metabolic syndrome (the Strong Heart Study). Am. J. Cardiol., 93, 40-44.
27. Bo, S.; Cavallo-Perin, P.; Scaglione, L. and Pagano, G. (1997) Heritability of cardiovascular risk parameters in subjects with in- creased susceptibility to non-insulin-dependent diabetes mellitus. Acta Diabetol., 34, 280-284.
28. Edwards, K.L.; Newman, B.; Mayer, E.; Selby, J.V.; Krauss, R.M. and Austin, M.A. (1997) Heritability of factors of the insulin resistance syndrome in women twins. Genet. Epidemiol., 14, 241-253.
29. Poulsen, P.; Kyvik, K.O.; Vaag, A. and Beck-Nielsen, H. (1999) Heritability of type II (non-insulin-dependent) diabetes mellitus and abnormal glucose tolerance--a population-based twin study. Diabetologia, 42, 139-145.
30. Brown, W.M.; Beck, S.R.; Lange, E.M.; Davis, C.C.; Kay, C.M.; Langefeld, C.D.; Rich, S.S. and Framingham, H.S. (2003) Age- stratified heritability estimation in the Framingham Heart Study families. BMC Genet., 4 (Suppl 1), S32.
31. Mayer, E.J.; Newman, B.; Austin, M.A.; Zhang, D.; Quesenberry, C.P. Jr.; Edwards, K. and Selby, J.V. (1996) Genetic and environ- mental influences on insulin levels and the insulin resistance syndrome: an analysis of women twins. Am. J. Epidemiol., 143, 323-332.
32. Beck-Nielsen, H. (1999) General characteristics of the insulin resistance syndrome: prevalence and heritability. European Group for the study of Insulin Resistance (EGIR). Drugs, 58 (Suppl 1), 7-10; discussion 75-82.
33. Lin, H.F.; Boden-Albala, B.; Juo, S.H.; Park, N.; Rundek, T. and Sacco, R.L. (2005) Heritabilities of the metabolic syndrome and its components in the Northern Manhattan Family Study. Diabetologia, 48, 2006-2012.
34. Poulsen, P.; Vaag, A.; Kyvik, K. and Beck-Nielsen, H. (2001) Genetic versus environmental aetiology of the metabolic syndrome among male and female twins. Diabetologia, 44, 537-543.
35. Fava, C.; Burri, P.; Almgren, P.; Groop, L., Hulthen, U.L. and Melander, O. (2004) Heritability of ambulatory and office blood pressure phenotypes in Swedish families. J. Hypertens., 22, 1717-1721.
36. Bochud, M.; Bovet, P.; Elston, R.C.; Paccaud, F.; Falconnet, C.; Maillard, M.; Shamlaye, C. and Burnier, M. (2005) High heritabil- ity of ambulatory blood pressure in families of East African descent. Hypertension, 45, 445-450.
37. Henneman, P.; Aulchenko, Y.S.; Frants, R.R.; van Dijk, K.W.; Oostra, B.A. and van Duijn, C.M. (2008) Prevalence and heritabil- ity of the metabolic syndrome and its individual components in a Dutch isolate: the Erasmus Rucphen Family study. J. Med. Genet., 45, 572-577.
38. Bellia, A.; Giardina, E.; Lauro, D.; Tesauro, M.; Di Fede, G.; Cusumano, G.; Federici, M.; Rini, G.B.; Novelli, G.; Lauro, R. and Sbraccia, P. (2009) The Linosa Study: epidemiological and heritability data of the metabolic syndrome in a Caucasian genetic isolate. Nutr. Metab. Cardiovasc. Dis., 19, 455-461.
39. Zhang, S.; Liu, X.; Yu, Y.; Hong, X.; Christoffel, K.K.; Wang, B.; Tsai, H.J.; Li, Z.; Tang, G.; Xing, H.; Brickman, W.J.; Zimmerman, D.; Xu, X. and Wang, X. (2009) Genetic and environmental contributions to phenotypic components of metabolic syndrome: a population-based twin study. Obesity (Silver Spring), 17, 1581-1587.
40. Chobanian, A.V.; Bakris, G.L.; Black, H.R.; Cushman, W.C.; Green, L.A.; Izzo, J.L. Jr.; Jones, D.W.; Materson, B.J.; Oparil, S.; Wright, J.T. Jr. and Roccella, E.J. (2003) Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension, 42, 1206-1252.
41. Dwyer, E.M.; Asif, M.; Ippolito, T. and Gillespie, M. (2000) Role of hypertension, diabetes, obesity, and race in the development of symptomatic myocardial dysfunction in a predominantly minority population with normal coronary arteries. Am. Heart J., 139, 297-304.
42. Galderisi, M.; Petrocelli, A.; Alfieri, A.; Garofalo, M. and de Divitiis, O. (1996) Impact of ambulatory blood pressure on left ventricular diastolic dysfunction in uncomplicated arterial systemic hypertension. Am. J. Cardiol., 77, 597-601.
43. Shapiro, L.M. and McKenna, W.J. (1984) Left ventricular hyper- trophy. Relation of structure to diastolic function in hypertension. Br. Heart J., 51, 637.
44. Roman, M.J.; Pickering, T.G.; Pini, R.; Schwartz, J.E. and Devereux, R.B. (1995) Prevalence and determinants of cardiac and vascular hypertrophy in hypertension. Hypertension, 26, 369-373.
45. Kronmal, R.A.; McClelland, R.L.; Detrano, R.; Shea, S.; Lima, J.A.; Cushman, M.; Bild, D.E. and Burke, G.L. (2007) Risk factors for the progression of coronary artery calcification in asymptomatic subjects: results from the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation, 115, 2722-2730.
46. Albert, C.M.; Chae, C.U.; Grodstein, F.; Rose, L.M.; Rexrode, K.M.; Ruskin, J.N.; Stampfer, M.J. and Manson, J.E. (2003) Prospective study of sudden cardiac death among women in the United States. Circulation, 107, 2096-2101.
47. Bhatia, R.S.; Tu, J.V.; Lee, D.S.; Austin, P.C.; Fang, J.; Haouzi, A.; Gong, Y. and Liu, P.P. (2006) Outcome of heart failure with pre- served ejection fraction in a population-based study. N. Engl. J. Med., 355, 260-269.
48. de Simone, G.; Devereux, R.B.; Chinali, M.; Roman, M.J.; Best, L.G.; Welty, T.K.; Lee, E.T.; Howard, B.V. and Strong Heart Study, I. (2006) Risk factors for arterial hypertension in adults with initial optimal blood pressure: the Strong Heart Study. Hypertension, 47, 162-167.
49. Arcucci, O.; de Simone, G.; Izzo, R.; Rozza, F.; Chinali, M.; Rao, M.A.; Bodenizza, C.; De Luca, N. and Trimarco, B. (2007) Asso- ciation of suboptimal blood pressure control with body size and metabolic abnormalities. J. Hypertens., 25, 2296-2300.
50. Despres, J.P.; Moorjani, S.; Lupien, P.J.; Tremblay, A.; Nadeau, A. and Bouchard, C. (1990) Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis, 10, 497-511.
51. Ross, R.; Aru, J.; Freeman, J.; Hudson, R. and Janssen, I. (2002) Abdominal adiposity and insulin resistance in obese men. Am. J. Physiol. Endocrinol. Metab., 282, E657-E663.
52. Ross, R.; Freeman, J.; Hudson, R. and Janssen, I. (2002) Abdomi- nal obesity, muscle composition, and insulin resistance in premenopausal women. J. Clin. Endocrinol. Metab., 87, 5044-5051.
53. Piche, M.E.; Lemieux, S.; Weisnagel, S.J.; Corneau, L.; Nadeau, A. and Bergeron, J. (2005). Relation of high-sensitivity C-reactive protein, interleukin-6, tumor necrosis factor-alpha, and fibrinogen to abdominal adipose tissue, blood pressure, and cholesterol and triglyceride levels in healthy postmenopausal women. Am. J. Cardiol., 96, 92-97.
54. Pascual, M.; Pascual, D.A.; Soria, F.; Vicente, T.; Hernandez, A.M.; Tebar, F.J. and Valdes, M. (2003) Effects of isolated obesity on systolic and diastolic left ventricular function. Heart, 89, 1152-1156.
55. Alaud-din, A.; Meterissian, S.; Lisbona, R.; MacLean, L.D. and Forse, R.A. (1990) Assessment of cardiac function in patients who were morbidly obese. Surgery, 108, 809-818.
56. Karason, K.; Wallentin, I.; Larsson, B. and Sjostrom, L. (1998) Effects of obesity and weight loss on cardiac function and valvular performance. Obes. Res., 6, 422-429.
57. Lauer, M.S.; Anderson, K.M.; Kannel, W.B. and Levy, D. (1991) The impact of obesity on left ventricular mass and geometry. The Framingham Heart Study. JAMA, 266, 231-236.
58. Alpert, M.A.; Lambert, C.R.; Panayiotou, H.; Terry, B.E.; Cohen, M.V.; Massey, C.V.; Hashimi, M.W. and Mukerji, V. (1995) Rela- tion of duration of morbid obesity to left ventricular mass, systolic function, and diastolic filling, and effect of weight loss. Am. J. Cardiol., 76, 1194-1197.
59. Kenchaiah, S.; Evans, J.C.; Levy, D.; Wilson, P.W.; Benjamin, E.J.; Larson, M.G.; Kannel, W.B. and Vasan, R.S. (2002) Obesity and the risk of heart failure. N. Engl. J. Med., 347, 305-313.
60. Bogers, R.P.; Bemelmans, W.J.; Hoogenveen, R.T.; Boshuizen, H.C.; Woodward, M.; Knekt, P.; van Dam, R.M.; Hu, F.B.; Visscher, T.L.; Menotti, A.; Thorpe, R.J.Jr.; Jamrozik, K.; Calling, S.; Strand, B.H. and Shipley, M.J. (2007) Association of over- weight with increased risk of coronary heart disease partly independent of blood pressure and cholesterol levels: a meta-analysis of 21 cohort studies including more than 300 000 persons. Arch. Intern. Med., 167, 1720-1728.
61. Adams, K.F.; Schatzkin, A.; Harris, T.B.; Kipnis, V.; Mouw, T.; Ballard-Barbash, R.; Hollenbeck, A. and Leitzmann, M.F. (2006) Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N. Engl. J. Med., 355, 763-778.
62. Flegal, K.M.; Graubard, B.I.; Williamson, D.F. and Gail, M.H. (2007) Cause-specific excess deaths associated with underweight, overweight, and obesity. JAMA, 298, 2028-2037.
63. Mehrabi, M.R.; Haslmayer, P.; Humpeler, S.; Strauss-Blasche, G.; Marktl, W.; Tamaddon, F.; Serbecic, N.; Wieselthaler, G.; Thalhammer, T.; Glogar, H.D. and Ekmekcioglu, C. (2003) Quantitative analysis of peroxisome proliferator-activated receptor gamma (PPARgamma) expression in arteries and hearts of patients with ischaemic or dilated cardiomyopathy. Eur. J. Heart Fail., 5, 733-739.
64. de Simone, G.; Devereux, R.B., Roman, M.J.; Alderman, M.H. and Laragh, J.H. (1994) Relation of obesity and gender to left ventricular hypertrophy in normotensive and hypertensive adults. Hypertension, 23, 600-606.
65. de Simone, G.; Gottdiener, J.S.; Chinali, M. and Maurer, M.S. (2008) Left ventricular mass predicts heart failure not related to previous myocardial infarction: the Cardiovascular Health Study. Eur. Heart J., 29, 741-747.
66. Allison, D.B.; Fontaine, K.R.; Manson, J.E.; Stevens, J. and VanItallie, T.B. (1999) Annual deaths attributable to obesity in the United States. JAMA, 282, 1530-1538.
67. Ingelsson, E.; Sullivan, L.M.; Fox, C.S.; Murabito, J.M.; Benjamin, E.J.; Polak, J.F.; Meigs, J.B.; Keyes, M.J.; O'Donnell, C.J.; Wang, T.J.; D'Agostino, R.B.; Wolf, P.A. and Vasan, R.S. (2007) Burden and prognostic importance of subclinical cardiovascular disease in overweight and obese individuals. Circulation, 116, 375-384.
68. Thomas, F.; Bean, K.; Pannier, B.; Oppert, J.M.; Guize, L. and Benetos, A. (2005) Cardiovascular mortality in overweight subjects: the key role of associated risk factors. Hypertension, 46, 654-659.
69. Lavie, C.J.; Milani, R.V.; Ventura, H.O.; Cardenas, G.A.; Mehra, M.R. and Messerli, F.H. (2007) Disparate effects of left ventricular geometry and obesity on mortality in patients with preserved left ventricular ejection fraction. Am. J. Cardiol., 100, 1460-1464.
70. Curtis, J.P.; Selter, J.G.; Wang, Y.; Rathore, S.S.; Jovin, I.S.; Jadbabaie, F.; Kosiborod, M.; Portnay, E.L.; Sokol, S.I.; Bader, F. and Krumholz, H.M. (2005) The obesity paradox: body mass index and outcomes in patients with heart failure. Arch. Intern. Med., 165, 55-61.
71. Pouliot, M.C.; Despres, J.P.; Nadeau, A.; Moorjani, S.; Prud'Homme, D.; Lupien, P.J.; Tremblay, A. and Bouchard, C. (1992) Visceral obesity in men: associations with glucose tolerance, plasma insulin, and lipoprotein levels. Diabetes, 41, 826-834.
72. Bansal, S.; Buring, J.E.; Rifai, N.; Mora, S.; Sacks, F.M. and Ridker, P.M. (2007) Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA, 298, 309-316.
73. Criqui, M.H.; Heiss, G.; Cohn, R.; Cowan, L.D.; Suchindran, C.M.; Bangdiwala, S.; Kritchevsky, S.; Jacobs, D.R.Jr.; O'Grady, H.K. and Davis, C.E. (1993) Plasma triglyceride level and mortality from coronary heart disease. N. Engl. J. Med., 328, 1220-1225.
74. Lemieux, I.; Almeras, N.; Mauriege, P.; Blanchet, C.; Dewailly, E.; Bergeron, J. and Despres, J.P. (2002) Prevalence of 'hypertriglyceridemic waist' in men who participated in the Quebec Health Survey: association with atherogenic and diabetogenic metabolic risk factors. Can. J. Cardiol., 18, 725-732.
75. Gordon, T.; Castelli, W.P.; Hjortland, M.C.; Kannel, W.B. and Dawber, T.R. (1977) High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am. J. Med., 62, 707-714.
76. Hanley, A.J.; Williams, K.; Stern, M.P. and Haffner, S.M. (2002) Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. Diabetes Care, 25, 1177-1184.
77. Doshi, K.B.; Kashyap, S.R.; Brennan, D.M.; Hoar, B.M.; Cho, L. and Hoogwerf, B.J. (2009) All-cause mortality risk predictors in a preventive cardiology clinic cohort-examining diabetes and individual metabolic syndrome criteria: a PRECIS database study. Diabetes Obes. Metab., 11, 102-108.
78. Gillum, R.F.; Mussolino, M.E. and Madans, J.H. (2000) Diabetes mellitus, coronary heart disease incidence, and death from all causes in African American and European American women: The NHANES I epidemiologic follow-up study. J. Clin. Epidemiol., 53, 511-518.
79. Preis, S.R.; Hwang, S.J.; Coady, S.; Pencina, M.J.; D'Agostino, R.B.Sr.; Savage, P.J.; Levy, D. and Fox, C.S. (2009) Trends in allcause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation, 119, 1728-1735.
80. Reaven, G.M.; Litheli, H. and Landsberg, L. (1996) Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system. N. Engl. J. Med., 334, 374.
81. Engeli, S. and Sharma, A.M. (2001) The renin-angiotensin system and natriuretic peptides in obesity-associated hypertension. J. Mol. Med., 79, 21-29.
82. Manzella, D.; Barbieri, M.; Rizzo, M.R.; Ragno, E.; Passariello, N.; Gambardella, A.; Marfella, R.; Giugliano, D. and Paolisso, G. (2001) Role of free fatty acids on cardiac autonomic nervous system in noninsulin-dependent diabetic patients: effects of metabolic control. J. Clin. Endocrinol. Metab., 86, 2769-2774.
83. Ceriello, A.; Taboga, C.; Tonutti, L.; Quagliaro, L.; Piconi, L.; Bais, B.; Da Ros, R. and Motz, E. (2002) Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment. Circulation, 106, 1211-1218.
84. Mizushige, K.; Yao, L.; Noma, T.; Kiyomoto, H.; Yu, Y.; Hosomi, N.; Ohmori, K. and Matsuo, H. (2000) Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulinresistant prediabetic stage of a type II diabetic rat model. Circulation, 101, 899-907.
85. Sciarretta, S.; Ferrucci, A.; Ciavarella, G.M.; De Paolis, P.; Venturelli, V.; Tocci, G.; De Biase, L.; Rubattu, S. and Volpe, M. (2007) Markers of inflammation and fibrosis are related to cardiovascular damage in hypertensive patients with metabolic syndrome. Am. J. Hypertens., 20, 784-791.
86. Gertow, K.; Pietilainen, K.H.; Yki-Jarvinen, H.; Kaprio, J.; Rissanen, A.; Eriksson, P.; Hamsten, A. and Fisher, R.M. (2004) Expression of fatty-acid-handling proteins in human adipose tissue in relation to obesity and insulin resistance. Diabetologia, 47, 1118-1125.
87. Miyaoka, K.; Kuwasako, T.; Hirano, K.; Nozaki, S.; Yamashita, S. and Matsuzawa, Y. (2001) CD36 deficiency associated with insulin resistance. Lancet, 357, 686-687.
88. de Simone, G.; Devereux, R.B.; Chinali, M.; Lee, E.T.; Galloway, J.M.; Barac, A.; Panza, J.A. and Howard, B.V. (2010) Diabetes and incident heart failure in hypertensive and normotensive participants of the Strong Heart Study. J. Hypertens., 28, 353-360.
89. Levy, D.; Larson, M.G.; Vasan, R.S.; Kannel, W.B. and Ho, K.K. (1996) The progression from hypertension to congestive heart failure. JAMA, 275, 1557-1562.
90. Stratton, I.M.; Adler, A.I.; Neil, H.A.; Matthews, D.R.; Manley, S.E.; Cull, C.A.; Hadden, D.; Turner, R.C. and Holman, R.R. (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ, 321, 405-412.
91. Gottdiener, J.S.; McClelland, R.L.; Marshall, R.; Shemanski, L.; Furberg, C.D.; Kitzman, D.W.; Cushman, M.; Polak, J.; Gardin, J.M.; Gersh, B.J.; Aurigemma, G.P. and Manolio, T.A. (2002) Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study. Ann. Intern. Med., 137, 631-639.
92. Gottdiener, J.S.; Arnold, A.M.; Aurigemma, G.P.; Polak, J.F.; Tracy, R.P.; Kitzman, D.W.; Gardin, J.M.; Rutledge, J.E. and Boineau, R.C. (2000) Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J. Am. Coll. Cardiol., 35, 1628-1637.
93. Diamant, M.; Lamb, H.J.; Groeneveld, Y.; Endert, E.L.; Smit, J.W.; Bax, J.J.; Romijn, J.A.; de Roos, A. and Radder, J.K. (2003) Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus. J. Am. Coll. Cardiol., 42, 328-335.
94. Chiu, H.C.; Kovacs, A.; Blanton, R.M.; Han, X.; Courtois, M.; Weinheimer, C.J.; Yamada, K.A.; Brunet, S.; Xu, H.; Nerbonne, J.M.; Welch, M.J.; Fettig, N.M.; Sharp, T.L.; Sambandam, N.; Olson, K.M.; Ory, D.S. and Schaffer, J.E. (2005) Transgenic expression of fatty acid transport protein 1 in the heart causes lipotoxic cardiomyopathy. Circ. Res., 96, 225-233.
95. Fang, Z.Y.; Najos-Valencia, O.; Leano, R. and Marwick, T.H. (2003) Patients with early diabetic heart disease demonstrate a normal myocardial response to dobutamine. J. Am. Coll. Cardiol., 42, 446-453.
96. Poornima, I.G.; Parikh, P. and Shannon, R.P. (2006) Diabetic cardiomyopathy: the search for a unifying hypothesis. Circ. Res., 98, 596-605.
97. Rijzewijk, L.J.; van der Meer, R.W.; Smit, J.W.; Diamant, M.; Bax, J.J.; Hammer, S.; Romijn, J.A.; de Roos, A. and Lamb, H.J. (2008) Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J. Am. Coll. Cardiol., 52, 1793-1799.
98. Von Bibra, H.; Thrainsdottir, I.S.; Hansen, A.; Dounis, V.; Malmberg, K. and Ryden, L. (2005) Tissue Doppler imaging for the detection and quantitation of myocardial dysfunction in patients with type 2 diabetes mellitus. Diab. Vasc. Dis. Res., 2, 24-30.
99. Westermann, D.; Rutschow, S.; Van Linthout, S.; Linderer, A.; Bucker-Gartner, C.; Sobirey, M.; Riad, A.; Pauschinger, M.; Schultheiss, H.P. and Tschope, C. (2006) Inhibition of p38 mitogen-activated protein kinase attenuates left ventricular dysfunction by mediating pro-inflammatory cardiac cytokine levels in a mouse model of diabetes mellitus. Diabetologia, 49, 2507-2513.
100. Fang, Z.Y.; Prins, J.B. and Marwick, T.H. (2004) Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr. Rev., 25, 543-567.
101. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). (2001) JAMA, 285, 2486-2497.
102. Wilson, P.W. and Meigs, J.B. (2008) Cardiometabolic risk: a Framingham perspective. Int. J. Obes. (Lond), 32 (Suppl 2), S17-S20.
103. Pyorala, K.; Ballantyne, C.M.; Gumbiner, B.; Lee, M.W.; Shah, A.; Davies, M.J.; Mitchel, Y.B.; Pedersen, T.R.; Kjekshus, J. and Scandinavian Simvastatin Survival, S. (2004) Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care, 27, 1735-1740.
104. Danesh, J.; Collins, R.; Appleby, P. and Peto, R. (1998) Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA, 279, 1477-1482.
105. Engstrom, G.; Lind, P.; Hedblad, B.; Stavenow, L.; Janzon, L. and Lindgarde, F. (2002) Effects of cholesterol and inflammationsensitive plasma proteins on incidence of myocardial infarction and stroke in men. Circulation, 105, 2632-2637.
106. Harris, T.B.; Ferrucci, L.; Tracy, R.P.; Corti, M.C.; Wacholder, S.; Ettinger, W.H.Jr.; Heimovitz, H.; Cohen, H.J. and Wallace, R. (1999) Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am. J. Med., 106, 506-512.
107. McGavock, J.M.; Lingvay, I.; Zib, I.; Tillery, T.; Salas, N.; Unger, R.; Levine, B.D.; Raskin, P.; Victor, R.G. and Szczepaniak, L.S. (2007) Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation, 116, 1170-1175.
108. Kotronen, A. and Yki-Jarvinen, H. (2008) Fatty liver: a novel component of the metabolic syndrome. Arterioscler. Thromb. Vasc. Biol., 28, 27-38.
109. Kraja, A.T.; Province, M.A.; Huang, P.; Jarvis, J.P.; Rice, T.; Cheverud, J.M. and Rao, D.C. (2008) Trends in metabolic syndrome and gene networks in human and rodent models. Endocr. Metab. Immune Disord. Drug Targets, 8, 198-207.
110. Mittra, S.; Bansal, V.S. and Bhatnagar, P.K. (2008) From a glucocentric to a lipocentric approach towards metabolic syndrome. Drug Discov. Today, 13, 211-218.
111. Chinetti, G.; Fruchart, J.C. and Staels, B. (2000) Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm. Res., 49, 497-505.
112. Suganami, T.; Nishida, J. and Ogawa, Y. (2005) A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha. Arterioscler. Thromb. Vasc. Biol., 25, 2062-2068.
113. McNeill, A.M.; Rosamond, W.D.; Girman, C.J.; Golden, S.H.; Schmidt, M.I.; East, H.E.; Ballantyne, C.M. and Heiss, G. (2005) The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care, 28, 385-390.
114. Heilbronn, L.; Smith, S.R. and Ravussin, E. (2004) Failure of fat cell proliferation, mitochondrial function and fat oxidation results in ectopic fat storage, insulin resistance and type II diabetes mellitus. Int. J. Obes. Relat. Metab. Disord., 28 (Suppl 4), S12-S21.
115. Sudano, I.; Spieker, L.E.; Noll, G.; Corti, R.; Weber, R. and Luscher, T.F. (2006) Cardiovascular disease in HIV infection. Am. Heart J., 151, 1147-1155.
116. Arner, P. (2005) Human fat cell lipolysis: biochemistry, regulation and clinical role. Best Pract. Res. Clin. Endocrinol. Metab., 19, 471-482.
117. Yoshii, H.; Lam, T.K.; Gupta, N.; Goh, T.; Haber, C.A.; Uchino, H.; Kim, T.T.; Chong, V.Z.; Shah, K.; Fantus, I.G.; Mari, A.; Kawamori, R. and Giacca, A. (2006) Effects of portal free fatty acid elevation on insulin clearance and hepatic glucose flux. Am. J. Physiol. Endocrinol. Metab., 290, E1089-E1097.
118. Randle, P.J.; Garland, P.B.; Hales, C.N. and Newsholme, E.A. (1963) The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet, 1, 785-789.
119. Unger, R.H. and Zhou, Y.T. (2001) Lipotoxicity of beta-cells in obesity and in other causes of fatty acid spillover. Diabetes, 40, S118.
120. Slawik, M. and Vidal-Puig, A.J. (2006) Lipotoxicity, overnutrition and energy metabolism in aging. Ageing Res. Rev., 5, 144-164.
121. van der Vusse, G.J.; van Bilsen, M.; Glatz, J.F.; Hasselbaink, D.M. and Luiken, J.J. (2002) Critical steps in cellular fatty acid uptake and utilization. Mol. Cell. Biochem., 239, 9-15.
122. de las Fuentes, L.; Herrero, P.; Peterson, L.R.; Kelly, D.P.; Gropler, R.J. and Davila-Roman, V.G.; eds. Myocardial fatty acid metabolism: independent predictor of left ventricular mass in hypertensive heart disease. Hypertension. Vol. 41. 2003. 83-87.
123. de las Fuentes, L.; Soto, P.F.; Cupps, B.P.; Pasque, M.K.; Herrero, P.; Gropler, R.J.; Waggoner, A.D. and Davila-Roman, V.G. (2006) Hypertensive left ventricular hypertrophy is associated with abnormal myocardial fatty acid metabolism and myocardial efficiency. J. Nucl. Cardiol., 13, 369-377.
124. Davila-Roman, V.G.; Vedala, G.; Herrero, P.; de las Fuentes, L.; Rogers, J.G.; Kelly, D.P. and Gropler, R.J. (2002) Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J. Am. Coll. Cardiol., 40, 271-277.
125. Finck, B.N.; Han, X.; Courtois, M.; Aimond, F.; Nerbonne, J.M.; Kovacs, A.; Gross, R.W. and Kelly, D.P. (2003) A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc. Natl. Acad. Sci. USA, 100, 1226-1231.
126. Barger, P.M.; Brandt, J.M.; Leone, T.C.; Weinheimer, C.J. and Kelly, D.P. (2000) Deactivation of peroxisome proliferatoractivated receptor-alpha during cardiac hypertrophic growth. J. Clin. Invest., 105, 1723-1730.
127. Djouadi, F.; Brandt, J.M.; Weinheimer, C.J.; Leone, T.C.; Gonzalez, F.J. and Kelly, D.P. (1999) The role of the peroxisome proliferator-activated receptor alpha (PPAR alpha) in the control of cardiac lipid metabolism. Prostaglandins Leukot. Essent. Fatty Acids, 60, 339-343.
128. de las Fuentes, L.; Waggoner, A.D.; Brown, A.L. and Davila-Roman, V.G. (2005) Plasma triglyceride level is an independent predictor of altered left ventricular relaxation. J. Am. Soc. Echocardiogr., 18, 1285-1291.
129. Abumrad, N.; Coburn, C. and Ibrahimi, A. (1999) Membrane proteins implicated in long-chain fatty acid uptake by mammalian cells: CD36, FATP and FABPm. Biochim. Biophys. Acta, 1441, 4-13.
130. Dyck, D.J. and Bonen, A. (1998) Muscle contraction increases palmitate esterification and oxidation and triacylglycerol oxidation. Am. J. Physiol. Endocrinol. Metab., 275, E888-E896.
131. Luiken, J.J.; Dyck, D.J.; Han, X.X.; Tandon, N.N.; Arumugam, Y.; Glatz, J.F. and Bonen, A. (2002) Insulin induces the translocation of the fatty acid transporter FAT/CD36 to the plasma membrane. Am. J. Physiol. Endocrinol. Metab., 282, E491-495.
132. Greenwalt, D.E.; Scheck, S.H. and Rhinehart-Jones, T. (1995) Heart CD36 expression is increased in murine models of diabetes and in mice fed a high fat diet. J. Clin. Invest., 96, 1382-1388.
133. Chabowski, A.; Coort, S.L.; Calles-Escandon, J.; Tandon, N.N.; Glatz, J.F.; Luiken, J.J. and Bonen, A. (2004) Insulin stimulates fatty acid transport by regulating expression of FAT/CD36 but not FABPpm. Am. J. Physiol. Endocrinol. Metab., 287, E781-E789.
134. Hajri, T.; Ibrahimi, A.; Coburn, C.T.; Knapp, F.F.Jr.; Kurtz, T.; Pravenec, M. and Abumrad, N.A. (2001) Defective fatty acid uptake in the spontaneously hypertensive rat is a primary determinant of altered glucose metabolism, hyperinsulinemia, and myocardial hypertrophy. J. Biol. Chem., 276, 23661-23666.
135. Pravenec, M.; Zidek, V.; Landa, V.; Simakova, M.; Mlejnek, P.; Kazdova, L.; Bila, V.; Krenova, D. and Kren, V. (2004) Genetic analysis of metabolic syndrome in the spontaneously hypertensive rat. Physiol. Res., 53 (Suppl 1), S15-22.
136. Finck, B.N.; Lehman, J.J.; Leone, T.C.; Welch, M.J.; Bennett, M.J.; Kovacs, A.; Han, X.; Gross, R.W.; Kozak, R.; Lopaschuk, G.D. and Kelly, D.P. (2002) The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J. Clin. Invest., 109, 121-130.
137. Sell, H.; Dietze-Schroeder, D. and Eckel, J. (2006) The adipocytemyocyte axis in insulin resistance. Trends Endocrinol. Metab., 17, 416-422.
138. Tontonoz, P.; Nagy, L.; Alvarez, J.G.; Thomazy, V.A. and Evans, R.M. (1998) PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell, 93, 241-252.
139. Nagy, L.; Tontonoz, P.; Alvarez, J.G.; Chen, H. and Evans, R.M. (1998) Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell, 93, 229-240.
140. Finck, B.N. and Kelly, D.P. (2006) PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J. Clin. Invest., 116, 615-622.
141. Lin, J.; Handschin, C. and Spiegelman, B.M. (2005) Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab., 1, 361-370.
142. Michael, L.F.; Wu, Z.; Cheatham, R.B.; Puigserver, P.; Adelmant, G.; Lehman, J.J.; Kelly, D.P. and Spiegelman, B.M. (2001) Restoration of insulin-sensitive glucose transporter (GLUT4) gene expression in muscle cells by the transcriptional coactivator PGC-1. Proc. Natl. Acad. Sci. USA, 98, 3820-3825.
143. Wu, Z.; Puigserver, P.; Andersson, U.; Zhang, C.; Adelmant, G.; Mootha, V.; Troy, A.; Cinti, S.; Lowell, B.; Scarpulla, R.C. and Spiegelman, B.M. (1999) Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell, 98, 115-124.
144. Zhou, Y.T.; Grayburn, P.; Karim, A.; Shimabukuro, M.; Higa, M.; Baetens, D.; Orci, L. and Unger, R.H. (2000) Lipotoxic heart disease in obese rats: implications for human obesity. Proc. Natl. Acad. Sci. USA, 97, 1784-1789.
145. Heymsfield, S.B.; Greenberg, A.S.; Fujioka, K.; Dixon, R.M.; Kushner, R.; Hunt, T.; Lubina, J.A.; Patane, J.; Self, B.; Hunt, P. and McCamish, M. (1999) Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA, 282, 1568-1575.
146. Petersen, K.F.; Oral, E.A.; Dufour, S.; Befroy, D.; Ariyan, C.; Yu, C.; Cline, G.W.; DePaoli, A.M.; Taylor, S.I.; Gorden, P. and Shulman, G.I. (2002) Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J. Clin. Invest., 109, 1345-1350.
147. Hukshorn, C.J.; Westerterp-Plantenga, M.S. and Saris, W.H. (2003) Pegylated human recombinant leptin (PEG-OB) causes additional weight loss in severely energy-restricted, overweight men. Am. J. Clin. Nutr., 77, 771-776.
148. Stern, N.; Osher, E. and Greenman, Y. (2007) Hypoadiponectinemia as a marker of adipocyte dysfunction--part II: the functional significance of low adiponectin secretion. J. Cardiometab. Syndr., 2, 288-294.
149. Stern, N.; Osher, E. and Greenman, Y. (2007) Hypoadiponectinemia as a marker of adipocyte dysfunction -- Part I: the biology of adiponectin. J. Cardiometab. Syndr., 2, 174-182.
150. Zhang, B.; Berger, J.; Hu, E.; Szalkowski, D.; White-Carrington, S.; Spiegelman, B.M. and Moller, D.E. (1996) Negative regulation of peroxisome proliferator-activated receptor-gamma gene expression contributes to the antiadipogenic effects of tumor necrosis factor-alpha. Mol. Endocrinol., 10, 1457-1466.
151. Kern, P.A.; Saghizadeh, M.; Ong, J.M.; Bosch, R.J.; Deem, R. and Simsolo, R.B. (1995) The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J. Clin. Invest., 95, 2111-2119.
152. Pradhan, A.D.; Manson, J.E.; Rifai, N.; Buring, J.E. and Ridker, P.M. (2001) C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA, 286, 327-334.
153. Cai, D.; Yuan, M.; Frantz, D.F.; Melendez, P.A.; Hansen, L.; Lee, J. and Shoelson, S.E. (2005) Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat. Med., 11, 183-190.
154. Yuan, M.; Konstantopoulos, N.; Lee, J.; Hansen, L.; Li, Z.W.; Karin, M. and Shoelson, S.E. (2001) Reversal of obesity- and dietinduced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science, 293, 1673-1677.
155. Jimi, E. and Ghosh, S. (2005) Role of nuclear factor-kappaB in the immune system and bone. Immunol. Rev., 208, 80-87.
156. Zingarelli, B. (2005) Nuclear factor-kappaB. Crit. Care Med., 33, S414-S416.
157. Valen, G.; Yan, Z.Q. and Hansson, G.K. (2001) Nuclear factor kappa-B and the heart. J. Am. Coll. Cardiol., 38, 307-314.
158. Jones, W.K.; Brown, M.; Ren, X.; He, S. and McGuinness, M. (2003) NF-kappaB as an integrator of diverse signaling pathways: the heart of myocardial signaling? Cardiovasc. Toxicol., 3, 229-254.
159. Liu, Y.H.; Wang, D.; Rhaleb, N.E.; Yang, X.P.; Xu, J.; Sankey, S.S.; Rudolph, A.E. and Carretero, O.A. (2005) Inhibition of p38 mitogen-activated protein kinase protects the heart against cardiac remodeling in mice with heart failure resulting from myocardial infarction. J. Card. Fail., 11, 74-81.
160. Kyriakis, J.M. and Avruch, J. (2001) Mammalian mitogenactivated protein kinase signal transduction pathways activated by stress and inflammation. Physiol. Rev., 81, 807-869.
161. Bueno, O.F. and Molkentin, J.D. (2002) Involvement of extracellular signal-regulated kinases 1/2 in cardiac hypertrophy and cell death. Circ. Res., 91, 776-781.
162. Liao, P.; Wang, S.Q.; Wang, S.; Zheng, M.; Zheng, M.; Zhang, S.J.; Cheng, H.; Wang, Y. and Xiao, R.P. (2002) p38 Mitogenactivated protein kinase mediates a negative inotropic effect in cardiac myocytes. Circ. Res., 90, 190-196.
163. Schoonjans, K.; Peinado-Onsurbe, J.; Lefebvre, A.M.; Heyman, R.A.; Briggs, M.; Deeb, S.; Staels, B. and Auwerx, J. (1996) PPARalpha and PPARgamma activators direct a distinct tissuespecific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J., 15, 5336-5348.
164. Ravingerova, T.; Barancik, M. and Strniskova, M. (2003) Mitogenactivated protein kinases: a new therapeutic target in cardiac pathology. Mol. Cell. Biochem., 247, 127-138.
165. Feingold, K.; Kim, M.S.; Shigenaga, J.; Moser, A. and Grunfeld, C. (2004) Altered expression of nuclear hormone receptors and coactivators in mouse heart during the acute-phase response. Am. J. Physiol. Endocrinol. Metab., 286, E201-207.
166. Krishnagopalan, S.; Kumar, A.; Parrillo, J.E. and Kumar, A. (2002) Myocardial dysfunction in the patient with sepsis. Curr. Opin. Crit. Care, 8, 376-388.
167. Pauschinger, M.; Chandrasekharan, K. and Schultheiss, H.P. (2004) Myocardial remodeling in viral heart disease: possible interactions between inflammatory mediators and MMP-TIMP system. Heart Fail Rev., 9, 21-31.
168. Aukrust, P.; Gullestad, L.; Ueland, T.; Damas, J.K. and Yndestad, A. (2005) Inflammatory and anti-inflammatory cytokines in chronic heart failure: potential therapeutic implications. Ann. Med., 37, 74-85.
169. Kanda, T. and Takahashi, T. (2004) Interleukin-6 and cardiovascular diseases. Jpn. Heart J., 45, 183-193.
170. Frantz, S.; Kobzik, L.; Kim, Y.D.; Fukazawa, R.; Medzhitov, R.; Lee, R.T. and Kelly, R.A. (1999) Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J. Clin. Invest., 104, 271-280.
171. Sivasubramanian, N.; Coker, M.L.; Kurrelmeyer, K.M.; MacLellan, W.R.; DeMayo, F.J.; Spinale, F.G. and Mann, D.L. (2001) Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor. Circulation, 104, 826-831.
172. Li, X.; Moody, M.R.; Engel, D.; Walker, S.; Clubb, F.J.Jr.; Sivasubramanian, N.; Mann, D.L. and Reid, M.B. (2000) Cardiacspecific overexpression of tumor necrosis factor-alpha causes oxi-dative stress and contractile dysfunction in mouse diaphragm. Circulation, 102, 1690-1696.
173. Wisniacki, N.; Taylor, W.; Lye, M. and Wilding, J.P. (2005) Insulin resistance and inflammatory activation in older patients with systolic and diastolic heart failure. Heart, 91, 32-37.
174. Levine, B.; Kalman, J.; Mayer, L.; Fillit, H.M. and Packer, M. (1990) Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N. Engl. J. Med., 323, 236-241.
175. Aukrust, P.; Ueland, T.; Lien, E.; Bendtzen, K.; Muller, F.; Andreassen, A.K.; Nordoy, I.; Aass, H.; Espevik, T.; Simonsen, S.; Froland, S.S. and Gullestad, L. (1999) Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am. J. Cardiol., 83, 376-382.
176. Testa, M.; Yeh, M.; Lee, P.; Fanelli, R.; Loperfido, F.; Berman, J.W. and LeJemtel, T.H. (1996) Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J. Am. Coll. Cardiol., 28, 964-971.
177. Torre-Amione, G.; Kapadia, S.; Benedict, C.; Oral, H.; Young, J.B. and Mann, D.L. (1996) Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J. Am. Coll. Cardiol., 27, 1201-1206.
178. Vasan, R.S.; Sullivan, L.M.; Roubenoff, R.; Dinarello, C.A.; Harris, T.; Benjamin, E.J.; Sawyer, D.B.; Levy, D.; Wilson, P.W. and D'Agostino, R.B. (2003) Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation, 107, 1486-1491.
179. Frantz, S.; Fraccarollo, D.; Wagner, H.; Behr, T.M.; Jung, P.; Angermann, C.E.; Ertl, G. and Bauersachs, J. (2003) Sustained activation of nuclear factor kappa B and activator protein 1 in chronic heart failure. Cardiovasc. Res., 57, 749-756.
180. Mahmud, A. and Feely, J. (2005) Arterial stiffness is related to systemic inflammation in essential hypertension. Hypertension, 46, 1118-1122.
181. Bautista, L.E.; Vera, L.M.; Arenas, I.A. and Gamarra, G. (2005) Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. J. Hum. Hypertens., 19, 149-154.
182. Kilickap, M.; Gurlek, A.; Dandachi, R.; Dincer, I.; Tutkak, H. and Oral, D. (2004) Tumour necrosis factor-alpha in diastolic dysfunction. Acta Cardiol., 59, 507-510.
183. Bruemmer, D.; Collins, A.R.; Noh, G.; Wang, W.; Territo, M.; Arias-Magallona, S.; Fishbein, M.C.; Blaschke, F.; Kintscher, U.; Graf, K.; Law, R.E. and Hsueh, W.A. (2003) Angiotensin IIaccelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice. J. Clin. Invest., 112, 1318-1331.
184. Rangaswami, H.; Bulbule, A. and Kundu, G.C. (2004) Nuclear factor-inducing kinase plays a crucial role in osteopontin-induced MAPK/IkappaBalpha kinase-dependent nuclear factor kappaBmediated promatrix metalloproteinase-9 activation. J. Biol. Chem., 279, 38921-38935.
185. de las Fuentes, L.; Gu, C.C.; Mathews, S.J.; Reagan, J.L.; Ruthmann, N.P.; Waggoner, A.D.; Lai, C.F.; Towler, D.A. and Davila-Roman, V.G. (2008) Osteopontin Promoter Polymorphism Is Associated With Increased Carotid Intima-Media Thickness. J. Am. Soc. Echocardiogr., 21, 954-960.
186. Ogata, T.; Miyauchi, T.; Sakai, S.; Takanashi, M.; Irukayama- Tomobe, Y. and Yamaguchi, I. (2004) Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor- alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway. J. Am. Coll. Cardiol., 43, 1481-1488.
187. Kai, H.; Kuwahara, F.; Tokuda, K. and Imaizumi, T. (2005) Diastolic dysfunction in hypertensive hearts: roles of perivascular inflammation and reactive myocardial fibrosis. Hypertens. Res., 28, 483-490.
188. Muller, D.N.; Dechend, R.; Mervaala, E.M.; Park, J.K.; Schmidt, F.; Fiebeler, A.; Theuer, J.; Breu, V.; Ganten, D.; Haller, H. and Luft, F.C. (2000) NF-kappaB inhibition ameliorates angiotensin IIinduced inflammatory damage in rats. Hypertension, 35, 193-201.
189. Hundal, R.S.; Petersen, K.F.; Mayerson, A.B.; Randhawa, P.S.; Inzucchi, S.; Shoelson, S.E. and Shulman, G.I. (2002) Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J. Clin. Invest., 109, 1321-1326.
190. Devaraj, S.; Chan, E. and Jialal, I. (2006) Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome. J. Clin. Endocrinol. Metab., 91, 4489-4496.
191. Tesauro, M.; Schinzari, F.; Rovella, V.; Melina, D.; Mores, N.; Barini, A.; Mettimano, M.; Lauro, D.; Iantorno, M.; Quon, M.J. and Cardillo, C. (2008) Tumor necrosis factor-alpha antagonism improves vasodilation during hyperinsulinemia in metabolic syndrome. Diabetes Care, 31, 1439-1441.
192. Kuwahara, F.; Kai, H.; Tokuda, K.; Takeya, M.; Takeshita, A.; Egashira, K. and Imaizumi, T. (2004) Hypertensive myocardial fibrosis and diastolic dysfunction: another model of inflammation? Hypertension, 43, 739-745.
193. Mann, D.L.; McMurray, J.J.; Packer, M.; Swedberg, K.; Borer, J.S.; Colucci, W.S.; Djian, J.; Drexler, H.; Feldman, A.; Kober, L.; Krum, H.; Liu, P.; Nieminen, M.; Tavazzi, L.; van Veldhuisen, D.J.; Waldenstrom, A.; Warren, M.; Westheim, A.; Zannad, F. and Fleming, T. (2004) Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation, 109, 1594-1602.
194. Chung, E.S.; Packer, M.; Lo, K.H.; Fasanmade, A.A. and Willerson, J.T. (2003) Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation, 107, 3133-3140.
195. Peraldi, P.; Xu, M. and Spiegelman, B.M. (1997) Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling. J. Clin. Invest., 100, 1863-1869.
196. Hill, M.R.; Clarke, S.; Rodgers, K.; Thornhill, B.; Peters, J.M.; Gonzalez, F.J. and Gimble, J.M. (1999) Effect of peroxisome proliferator- activated receptor alpha activators on tumor necrosis factor expression in mice during endotoxemia. Infect. Immun., 67, 3488-3493.
197. Delerive, P.; Fruchart, J.C. and Staels, B. (2001) Peroxisome proliferator-activated receptors in inflammation control. J. Endocrinol., 169, 453-459.
198. Rival, Y.; Beneteau, N.; Taillandier, T.; Pezet, M.; Dupont-Passelaigue, E.; Patoiseau, J.F.; Junquero, D.; Colpaert, F.C. and Delhon, A. (2002) PPARalpha and PPARdelta activators inhibit cytokine- induced nuclear translocation of NF-kappaB and expression of VCAM-1 in EAhy926 endothelial cells. Eu. J. Pharmacol., 435, 143-151.
199. Ye, P.; Fang, H.; Zhou, X.; He, Y.L. and Liu, Y.X. (2004) Effect of peroxisome proliferator-activated receptor activators on tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes. Chin. Med. Sci. J., 19, 243-247.
200. Watanabe, K.; Fujii, H.; Takahashi, T.; Kodama, M.; Aizawa, Y.; Ohta, Y.; Ono, T.; Hasegawa, G.; Naito, M.; Nakajima, T.; Kamijo, Y.; Gonzalez, F.J. and Aoyama, T. (2000) Constitutive regulation of cardiac fatty acid metabolism through peroxisome proliferatoractivated receptor alpha associated with age-dependent cardiac toxicity. J. Biol. Chem., 275, 22293-22299.
201. Planavila, A.; Calvo, R.R. and Vazquez-Carrera, M. (2006) Peroxisome proliferator-activated receptors and the control of fatty acid oxidation in cardiac hypertrophy. Mini Rev. Med. Chem., 6, 357-363.
202. Dattilo, A.M. and Kris-Etherton, P.M. (1992) Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am. J. Clin. Nutr., 56, 320-328.
203. de las Fuentes, L.; Waggoner, A.D.; Mohammed, B.S.; Stein, R.I.; Miller, B.V.; Foster, G.D.; Wyatt, H.R.; Klein, S. and Davila- Roman, V.G. (2009) Effect of moderate diet-induced weight loss and weight regain on cardiovascular structure and function. J. Am. Coll. Cardiol., 54, 2376-2381.
204. Fox, A.A.; Thompson, J.L.; Butterfield, G.E.; Gylfadottir, U.; Moynihan, S. and Spiller, G. (1996) Effects of diet and exercise on common cardiovascular disease risk factors in moderately obese older women. Am. J. Clin. Nutr., 63, 225-233.
205. Alpert, M.A.; Terry, B.E.; Mulekar, M.; Cohen, M.V.; Massey, C.V.; Fan, T.M.; Panayiotou, H. and Mukerji, V. (1997) Cardiac morphology and left ventricular function in normotensive morbidly obese patients with and without congestive heart failure, and effect of weight loss. Am. J. Cardiol., 80, 736-740.
206. Juhaeri, Stevens, J.; Chambless, L.E.; Nieto, F.J.; Jones, D.; Schreiner, P.; Arnett, D. and Cai, J. (2003) Associations of weight loss and changes in fat distribution with the remission of hypertension in a bi-ethnic cohort: the Atherosclerosis Risk in Communities Study. Prev. Med., 36, 330-339.
207. Fisher, R.M.; Hoffstedt, J.; Hotamisligil, G.S.; Thorne, A. and Ryden, M. (2002) Effects of obesity and weight loss on the expression of proteins involved in fatty acid metabolism in human adipose tissue. Int. J. Obes. Relat. Metab. Disord., 26, 1379-1385.
208. Mavri, A.; Stegnar, M.; Sentocnik, J.T. and Videcnik, V. (2001) Impact of weight reduction on early carotid atherosclerosis in obese premenopausal women. Obes. Res., 9, 511-516.
209. Van Gaal, L.F.; Wauters, M.A. and De Leeuw, I.H. (1997) The beneficial effects of modest weight loss on cardiovascular risk factors. Int. J. Obes. Relat. Metab. Disord., 21(Suppl 1), S5-9.
210. Laimer, M.; Ebenbichler, C.F.; Kaser, S.; Sandhofer, A.; Weiss, H.; Nehoda, H.; Aigner, F. and Patsch, J.R. (2002) Markers of chronic inflammation and obesity: a prospective study on the reversibility of this association in middle-aged women undergoing weight loss by surgical intervention. Int. J. Obes. Relat. Metab. Disord., 26, 659-662.
211. Monzillo, L.U.; Hamdy, O.; Horton, E.S.; Ledbury, S.; Mullooly, C.; Jarema, C.; Porter, S.; Ovalle, K.; Moussa, A. and Mantzoros, C.S. (2003) Effect of lifestyle modification on adipokine levels in obese subjects with insulin resistance. Obes. Res., 11, 1048-1054.
212. Kopp, H.P.; Krzyzanowska, K.; Mohlig, M.; Spranger, J.; Pfeiffer, A.F. and Schernthaner, G. (2005) Effects of marked weight loss on plasma levels of adiponectin, markers of chronic subclinical inflammation and insulin resistance in morbidly obese women. Int. J. Obes. (Lond), 29, 766-771.
213. Manigrasso, M.R.; Ferroni, P.; Santilli, F.; Taraborelli, T.; Guagnano, M.T.; Michetti, N. and Davi, G. (2005) Association between circulating adiponectin and interleukin-10 levels in android obesity: effects of weight loss. J. Clin. Endocrinol. Metab., 90, 5876-5879.
214. Luyckx, F.H.; Lefebvre, P.J. and Scheen, A.J. (2000) Nonalcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss. Diabetes Metab., 26, 98-106.
215. Way, J.M.; Harrington, W.W.; Brown, K.K.; Gottschalk, W.K.; Sundseth, S.S.; Mansfield, T.A.; Ramachandran, R.K.; Willson, T.M. and Kliewer, S.A. (2001) Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues. Endocrinology, 142, 1269-1277.
216. Sato, O.; Kuriki, C.; Fukui, Y. and Motojima, K. (2002) Dual promoter structure of mouse and human fatty acid translocase/CD36 genes and unique transcriptional activation by peroxisome proliferator- activated receptor alpha and gamma ligands. J. Biol. Chem., 277, 15703-15711.
217. Tan, N.S.; Shaw, N.S.; Vinckenbosch, N.; Liu, P.; Yasmin, R.; Desvergne, B.; Wahli, W. and Noy, N. (2002) Selective cooperation between fatty acid binding proteins and peroxisome proliferator- activated receptors in regulating transcription. Mol. Cell. Biol., 22, 5114-5127.
218. Barak, Y.; Nelson, M.C.; Ong, E.S.; Jones, Y.Z.; Ruiz-Lozano, P.; Chien, K.R.; Koder, A. and Evans, R.M. (1999) PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol. Cell, 4, 585-595.
219. Miles, P.D.; Barak, Y.; He, W.; Evans, R.M. and Olefsky, J.M. (2000) Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency. J. Clin. Invest., 105, 287-292.
220. Kubota, N.; Terauchi, Y.; Miki, H.; Tamemoto, H.; Yamauchi, T.; Komeda, K.; Satoh, S.; Nakano, R.; Ishii, C.; Sugiyama, T.; Eto, K.; Tsubamoto, Y.; Okuno, A.; Murakami, K.; Sekihara, H.; Hasegawa, G.; Naito, M.; Toyoshima, Y.; Tanaka, S.; Shiota, K.; Kitamura, T.; Fujita, T.; Ezaki, O.; Aizawa, S. and Kadowaki, T. (1999) PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol. Cell, 4, 597-609.
221. Jones, J.R.; Barrick, C.; Kim, K.A.; Lindner, J.; Blondeau, B.; Fujimoto, Y.; Shiota, M.; Kesterson, R.A.; Kahn, B.B. and Magnuson, M.A. (2005) Deletion of PPARgamma in adipose tissues of mice protects against high fat diet-induced obesity and insulin resistance. Proc. Natl. Acad. Sci. USA, 102, 6207-6212.
222. Nicol, C.J.; Adachi, M.; Akiyama, T.E. and Gonzalez, F.J. (2005) PPARgamma in endothelial cells influences high fat diet-induced hypertension. Am. J. Hypertens., 18, 549-556.
223. Muhlhausler, B.S.; Morrison, J.L. and McMillen, I.C. (2009) Rosiglitazone increases the expression of peroxisome proliferatoractivated receptor-gamma target genes in adipose tissue, liver, and skeletal muscle in the sheep fetus in late gestation. Endocrinology, 150, 4287-4294.
224. Orasanu, G.; Ziouzenkova, O.; Devchand, P.R.; Nehra, V.; Hamdy, O.; Horton, E.S. and Plutzky, J. (2008) The peroxisome proliferator- activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alphadependent manner in vitro and in vivo in mice. J. Am. Coll. Cardiol., 52, 869-881.
225. Delea, T.E.; Edelsberg, J.S.; Hagiwara, M.; Oster, G. and Phillips, L.S. (2003) Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. Diabetes Care, 26, 2983-2989.
226. Guan, Y.; Hao, C.; Cha, D.R.; Rao, R.; Lu, W.; Kohan, D.E.; Magnuson, M.A.; Redha, R.; Zhang, Y. and Breyer, M.D. (2005) Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat. Med., 11, 861-866.
227. Caballero, A.E.; Saouaf, R.; Lim, S.C.; Hamdy, O.; Abou-Elenin, K.; O'Connor, C.; Logerfo, F.W.; Horton, E.S. and Veves, A. (2003) The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebocontrolled randomized clinical trial. Metabolism, 52, 173-180.
228. Takagi, T.; Okura, H.; Kobayashi, Y.; Kataoka, T.; Taguchi, H.; Toda, I.; Tamita, K.; Yamamuro, A.; Sakanoue, Y.; Ito, A.; Yanagi, S.; Shimeno, K.; Waseda, K.; Yamasaki, M.; Fitzgerald, P.J.; Ikeno, F.; Honda, Y.; Yoshiyama, M.; Yoshikawa, J. and Investigators, P. (2009) A prospective, multicenter, randomized trial to assess efficacy of pioglitazone on in-stent neointimal suppression in type 2 diabetes: POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study). JACC Cardiovasc. Interv., 2, 524-531.
229. Erdmann, E.; Dormandy, J.; Wilcox, R.; Massi-Benedetti, M. and Charbonnel, B. (2007) PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study. Vasc. Health Risk Manag., 3, 355-370.
230. Dormandy, J.A.; Charbonnel, B.; Eckland, D.J.; Erdmann, E.; Massi-Benedetti, M.; Moules, I.K.; Skene, A.M.; Tan, M.H.; Lefebvre, P.J.; Murray, G.D.; Standl, E.; Wilcox, R.G.; Wilhelmsen, L.; Betteridge, J.; Birkeland, K.; Golay, A.; Heine, R.J.; Koranyi, L.; Laakso, M.; Mokan, M.; Norkus, A.; Pirags, V.; Podar, T.; Scheen, A.; Scherbaum, W.; Schernthaner, G.; Schmitz, O.; Skrha, J.; Smith, U.; Taton, J. and investigators, P.R. (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet, 366, 1279-1289.
231. Benkirane, K.; Viel, E.C.; Amiri, F. and Schiffrin, E.L. (2006) Peroxisome proliferator-activated receptor gamma regulates angiotensin II-stimulated phosphatidylinositol 3-kinase and mitogenactivated protein kinase in blood vessels in vivo. Hypertension, 47, 102-108.
232. Cha, B.S.; Ciaraldi, T.P.; Park, K.S.; Carter, L.; Mudaliar, S.R. and Henry, R.R. (2005) Impaired fatty acid metabolism in type 2 diabetic skeletal muscle cells is reversed by PPARgamma agonists. Am. J. Physiol. Endocrinol. Metab., 289, E151-E159.
233. Savage, D.B.; Tan, G.D.; Acerini, C.L.; Jebb, S.A.; Agostini, M.; Gurnell, M.; Williams, R.L.; Umpleby, A.M.; Thomas, E.L.; Bell, J.D.; Dixon, A.K.; Dunne, F.; Boiani, R.; Cinti, S.; Vidal-Puig, A.; Karpe, F.; Chatterjee, V.K. and O'Rahilly, S. (2003) Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptorgamma. Diabetes, 52, 910-917.
234. Faich, G.A. and Moseley, R.H. (2001) Troglitazone (Rezulin) and hepatic injury. Pharmacoepidemiol. Drug Saf., 10, 537-547.
235. St John Sutton, M.; Rendell, M.; Dandona, P.; Dole, J.F.; Murphy, K.; Patwardhan, R.; Patel, J. and Freed, M. (2002) A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care, 25, 2058-2064.
236. Horio, T.; Suzuki, M.; Suzuki, K.; Takamisawa, I.; Hiuge, A.; Kamide, K.; Takiuchi, S.; Iwashima, Y.; Kihara, S.; Funahashi, T.; Yoshimasa, Y. and Kawano, Y. (2005) Pioglitazone improves left ventricular diastolic function in patients with essential hypertension. Am. J. Hypertens., 18, 949-957.
237. Home, P.D.; Pocock, S.J.; Beck-Nielsen, H.; Curtis, P.S.; Gomis, R.; Hanefeld, M.; Jones, N.P.; Komajda, M.; McMurray, J.J. and Team, R.S. (2009) Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet, 373, 2125-2135.
238. Karter, A.J.; Ahmed, A.T.; Liu, J.; Moffet, H.H. and Parker, M.M. (2005) Pioglitazone initiation and subsequent hospitalization for congestive heart failure. Diabet. Med., 22, 986-993.
239. Nissen, S.E. and Wolski, K. (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med., 356, 2457-2471.
240. Erbe, D.V.; Gartrell, K.; Zhang, Y.L.; Suri, V.; Kirincich, S.J.; Will, S.; Perreault, M.; Wang, S. and Tobin, J.F. (2006) Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists. Vascul. Pharmacol., 45, 154-162.
241. Schupp, M.; Janke, J.; Clasen, R.; Unger, T. and Kintscher, U. (2004) Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation, 109, 2054-2057.
242. Yamamoto, K.; Ohki, R.; Lee, R.T.; Ikeda, U. and Shimada, K. (2001) Peroxisome proliferator-activated receptor gamma activators inhibit cardiac hypertrophy in cardiac myocytes. Circulation, 104, 1670-1675.
243. Clasen, R.; Schupp, M.; Foryst-Ludwig, A.; Sprang, C.; Clemenz, M.; Krikov, M.; Thone-Reineke, C.; Unger, T. and Kintscher, U. (2005) PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension, 46, 137-143.
244. Janke, J.; Schupp, M.; Engeli, S.; Gorzelniak, K.; Boschmann, M.; Sauma, L.; Nystrom, F.H.; Jordan, J.; Luft, F.C. and Sharma, A.M. (2006) Angiotensin type 1 receptor antagonists induce human in invitro adipogenesis through peroxisome proliferator-activated receptor-gamma activation. J. Hypertens., 24, 1809-1816.
245. Nagel, J.M.; Tietz, A.B.; Goke, B. and Parhofer, K.G. (2006) The effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjects. Metabolism, 55, 1149-1154.
246. Henry, R.R.; Lincoff, A.M.; Mudaliar, S.; Rabbia, M.; Chognot, C. and Herz, M. (2009) Effect of the dual peroxisome proliferatoractivated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet, 374, 126-135.
247. Szmitko, P.E. and Verma, S. (2008) The endocannabinoid system and cardiometabolic risk. Atherosclerosis, 199, 248-256.
248. Pi-Sunyer, F.X.; Aronne, L.J.; Heshmati, H.M.; Devin, J.; Rosenstock, J. and Group, R.I.-N.A.S. (2006) Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA, 295, 761-775.
249. Ho, S.Y. (2002) Anatomy of the mitral valve. Heart, 88 (Suppl 4), iv5-10.
250. Addy, C.; Rothenberg, P.; Li, S.; Majumdar, A.; Agrawal, N.; Li, H.; Zhong, L.; Yuan, J.; Maes, A.; Dunbar, S.; Cote, J.; Rosko, K.; Van Dyck, K.; De Lepeleire, I.; de Hoon, J.; Van Hecken, A.; Depre, M.; Knops, A.; Gottesdiener, K.; Stoch, A. and Wagner, J. (2008) Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers. J. Clin. Pharmacol., 48, 734-744.